Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 119

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 119
---
 Collaborations: Forge and maintain strategic partnerships with academic institutions, research organizations, and cancer          
 advocacy groups to advance ARB’s development and adoption. Engaging with the broader oncology community can foster support            
 for ARB’s innovative approach to cancer treatment. We also plan to engage with major pharmaceutical companies regarding existing      
 cancer therapy products in the market, aiming to collaborate and integrate our combination therapy nano-ARB with approved treatments. 
 This collaboration aims to facilitate lower doses, improve toxicity profiles, enhance treatment efficacy, and reduce resistance to    
 current therapies.                                                                                                                    |

By adhering to this multi-path strategy,
we are planning to ensure that the ARB project is optimally positioned to navigate the complexities of the oncology field, from developmental
hurdles to regulatory approvals and market entry, aligning our efforts with the ultimate goal of transforming cancer treatment paradigms.

In this regard, we note that there can be no
assurance that we will be able to secure above referenced development partnerships or collaborations. However, we do not rely on public
funding and continue to pursue multiple funding strategies to support our development programs. If we are unable to successfully contract
with third parties for development support, we may need to target less indications and/or raise additional funds to continue advancing
our product candidates.

<div align='center'>77</div>

Manufacturing

Development plan and Chemistry, Manufacturing, and Controls (CMC)

CMC activities are centered on the development
of manufacturing methods, scaling up processes, and preparing Nano-Mupirocin for clinical trials. We do not own or operate, and currently
have no plans to establish, any manufacturing facilities.

We have engaged, and currently rely on, a single
third-party CMO, STA Pharmaceutical Hong Kong Limited, a Hong Kong corporation and an affiliated company of WuXi AppTec a global pharmaceutical
CRDMO providing integrated drug discovery, development & manufacturing services across Asia, Europe & North America., for the
supply of our product candidates for use in our preclinical studies and future clinical trials. Should our CMO become unavailable to
us for any reason, we believe that there are a number of potential replacements, although we would incur delay and cost in identifying
and qualifying such replacements. We maintain a master services agreement with STA Pharmaceuticals pursuant to which it has agreed to
provide biologics development and manufacturing services on a per-project basis. We may terminate the master services agreement at any
time for convenience in accordance with the terms of the agreement. The agreement includes confidentiality